LG Chem Set to Unveil Anticancer Drugs, Begin Ficlatuzumab Phase 3 Clinical Trial
In a bid to accelerate the development of anti-cancer drugs, South Korean chemical company LG Chem announced on Wednesday that its subsidiary AVEO Pharmaceuticals has commenced the U.S. phase 3 clinical trial for Ficlatuzumab – a novel drug designed for human papillomavirus (HPV) negative head and neck cancer. This marks a crucial step forward in […]
In a bid to accelerate the development of anti-cancer drugs, South Korean chemical company LG Chem announced on Wednesday that its subsidiary AVEO Pharmaceuticals has commenced the U.S. phase 3 clinical trial for Ficlatuzumab – a novel drug designed for human papillomavirus (HPV) negative head and neck cancer. This marks a crucial step forward in […]
